160 related articles for article (PubMed ID: 11049026)
1. Immunotherapeutic strategies for the treatment of plasma cell malignancies.
Treon SP; Raje N; Anderson KC
Semin Oncol; 2000 Oct; 27(5):598-613. PubMed ID: 11049026
[TBL] [Abstract][Full Text] [Related]
2. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
[TBL] [Abstract][Full Text] [Related]
3. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
Treon SP; Kelliher A; Keele B; Frankel S; Emmanouilides C; Kimby E; Schlossman R; Mitsiades N; Mitsiades C; Preffer F; Anderson KC
Semin Oncol; 2003 Apr; 30(2):248-52. PubMed ID: 12720146
[TBL] [Abstract][Full Text] [Related]
4. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
5. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens.
Treon SP; Shima Y; Grossbard ML; Preffer FI; Belch AR; Pilarski LM; Anderson KC
Ann Oncol; 2000; 11 Suppl 1():107-11. PubMed ID: 10707790
[TBL] [Abstract][Full Text] [Related]
6. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
7. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies.
Leitch HA; Connors JM
Curr Opin Investig Drugs; 2005 Jun; 6(6):597-604. PubMed ID: 15988911
[TBL] [Abstract][Full Text] [Related]
8. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.
Treon SP; Anderson KC
Semin Oncol; 2000 Dec; 27(6 Suppl 12):79-85. PubMed ID: 11226004
[TBL] [Abstract][Full Text] [Related]
9. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
10. Active immunotherapy of multiple myeloma.
Houet L; Veelken H
Eur J Cancer; 2006 Jul; 42(11):1653-60. PubMed ID: 16797966
[TBL] [Abstract][Full Text] [Related]
11. Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother (1991); 2001 May; 24(3):263-271. PubMed ID: 11395643
[TBL] [Abstract][Full Text] [Related]
12. Cellular immunotherapy for multiple myeloma.
Rosenblatt J; Avigan D
Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455
[TBL] [Abstract][Full Text] [Related]
13. Antibody therapy for treatment of multiple myeloma.
Maloney DG; Donovan K; Hamblin TJ
Semin Hematol; 1999 Jan; 36(1 Suppl 3):30-3. PubMed ID: 9989487
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in multiple myeloma: current strategies and future prospects.
Yi Q
Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
[TBL] [Abstract][Full Text] [Related]
15. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.
Treon SP; Agus DB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother (1991); 2001 May; 24(3):272-279. PubMed ID: 11395644
[TBL] [Abstract][Full Text] [Related]
16. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
17. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M
J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214
[TBL] [Abstract][Full Text] [Related]
18. DC-based immunotherapy of B-cell malignancies.
Reichardt VL; Brossart P
Cytotherapy; 2004; 6(1):62-7. PubMed ID: 14985168
[TBL] [Abstract][Full Text] [Related]
19. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
20. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
